Danoprevir for the Treatment of Hepatitis C Virus Infection: Design, Development, and Place in Therapy

On June 8, 2018, an NS3/4A protease inhibitor called danoprevir was approved in China to treat the infections of HCV genotype (GT) 1b – the most common HCV genotype worldwide. Based on phase 2 and 3 clinical trials, the 12-week regimen of ritonavir-boosted danoprevir (danoprevir/r) plus peginterfero...

Descripción completa

Detalles Bibliográficos
Autores principales: Miao, Miao, Jing, Xixi, De Clercq, Erik, Li, Guangdi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368560/
https://www.ncbi.nlm.nih.gov/pubmed/32764876
http://dx.doi.org/10.2147/DDDT.S254754

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368560/
https://www.ncbi.nlm.nih.gov/pubmed/32764876
http://dx.doi.org/10.2147/DDDT.S254754

Ejemplares similares